Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cetuximab added to capecitabine, oxaliplatin and bevacizumab in patients with previously untreated advanced colorectal carcinoma, a randomised phase III study.

Trial Profile

Cetuximab added to capecitabine, oxaliplatin and bevacizumab in patients with previously untreated advanced colorectal carcinoma, a randomised phase III study.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jun 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Cetuximab (Primary) ; Capecitabine; Oxaliplatin
  • Indications Carcinoma; Colorectal cancer
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Acronyms CAIRO2
  • Most Recent Events

    • 11 Jun 2020 Results of population pharmacodynamic modeling characterizing the changes in tumor size and CTC count, using patient data from this study published in the Clinical Cancer Research
    • 11 Oct 2016 Results (n=182) analysing copy number alterations as predictive biomarkers to bevacizumab response, presented at the 41st European Society for Medical Oncology Congress.
    • 01 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top